Group R&D expenses: ¥418 million
First written in FY2016-Q2. 5 of 34 entries say "Restated". Latest entry: FY2026-H1.
42 other companies' latest entry also says "Other".
- FY2026-H1Decline in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the current consolidated interim fiscal period were ¥426 million.」
R&D expenses for the interim period were ¥426 million, down from ¥495 million in the same period of the previous year. - FY2025-H1Decline in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the current consolidated interim fiscal period were ¥465 million.」
R&D expenses for the interim period were ¥465 million, down from ¥495 million in the same period of the previous year. - FY2024Increase in R&D ExpensesAnnual report
「Total R&D expenses for the current consolidated fiscal year were ¥1,054 million.」
Full-year R&D expenses were ¥1,054 million, up from ¥895 million in the previous fiscal year. - FY2024-Q2Increase in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the second quarter of the current consolidated fiscal year were ¥495 million.」
R&D expenses for the cumulative period through the second quarter were ¥495 million, up from ¥412 million in the same period of the previous year. - FY2024-Q1R&D expenses increased year on yearAnnual report
「The total R&D expenses for the Group during the cumulative period through the first quarter of the current consolidated fiscal year were ¥249 million.」
R&D expenses for the cumulative period through the first quarter were ¥249 million, up from ¥195 million in the same period of the previous year. - FY2023-Q3Increase in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the third quarter of the current consolidated fiscal year were ¥656 million.」
R&D expenses for the cumulative period through the third quarter were ¥656 million, up from ¥616 million in the same period of the previous year. - FY2023-Q2R&D expenses increased year on yearAnnual report
「The total R&D expenses for the Group during the cumulative period through the second quarter of the current consolidated fiscal year were ¥412 million.」
R&D expenses for the cumulative period through the second quarter were ¥412 million, up from ¥402 million in the same period of the previous year. - FY2023-Q1Decline in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the first quarter of the current consolidated fiscal year were ¥187 million.」
First-quarter R&D expenses were ¥187 million, down from ¥195 million in the same period of the previous year. - FY2022Decline in R&D ExpensesAnnual report
「Total R&D expenses for the current consolidated fiscal year were ¥825 million.」
Full-year R&D expenses were ¥825 million, down from ¥964 million in the previous fiscal year. - FY2022-Q3Decline in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the third quarter of the current consolidated fiscal year were ¥616 million.」
R&D expenses for the cumulative period through the third quarter were ¥616 million, down from ¥710 million in the same period of the previous year. - FY2022-Q2Decline in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the second quarter of the current consolidated fiscal year were ¥402 million.」
R&D expenses for the cumulative period through the second quarter were ¥402 million, down from ¥489 million in the same period of the previous year. - FY2022-Q1Decline in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the first quarter of the current consolidated fiscal year were ¥195 million.」
Quarterly R&D expenses were ¥195 million, down from ¥224 million in the same period of the previous year. - FY2021-Q3Increase in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the third quarter of the current consolidated fiscal year were ¥710 million.」
R&D expenses for the cumulative period through the third quarter were ¥710 million, up from ¥518 million in the same period of the previous year. - FY2021-Q2Increase in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the second quarter of the current consolidated fiscal year were ¥489 million.」
R&D expenses for the cumulative period through the second quarter were ¥489 million, up from ¥332 million in the same period of the previous year. - FY2021-Q1Increase in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the first quarter of the current consolidated fiscal year were ¥224 million.」
First-quarter R&D expenses were ¥224 million, up from ¥172 million in the same period of the previous year. - FY2020Increase in R&D ExpensesAnnual report
「Total R&D expenses for the current consolidated fiscal year were ¥768 million.」
Full-year R&D expenses were ¥768 million, up from ¥735 million in the previous fiscal year. - FY2020-Q3Decline in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the third quarter of the current consolidated fiscal year were ¥518 million.」
R&D expenses for the cumulative period through the third quarter were ¥518 million, down from ¥543 million in the same period of the previous year. - FY2020-Q2Decline in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the second quarter of the current consolidated fiscal year were ¥332 million.」
R&D expenses for the cumulative period through the second quarter were ¥332 million, down from ¥356 million in the same period of the previous year. - FY2020-Q1R&D expenses increased slightly year on yearAnnual report
「The total R&D expenses for the Group during the cumulative period through the first quarter of the current consolidated fiscal year were ¥172 million.」
First-quarter R&D expenses were ¥172 million, a slight increase from ¥171 million in the same period of the previous year. - FY2019Decline in R&D ExpensesAnnual report
「Total R&D expenses for the current consolidated fiscal year were ¥735 million.」
Full-year R&D expenses were ¥735 million, down from ¥810 million in the previous fiscal year. Pharmaceuticals and FC accounted for ¥368 million, and Chemicals accounted for ¥367 million. - FY2019-Q3Decline in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the third quarter of the current consolidated fiscal year were ¥543 million.」
R&D expenses for the cumulative period through the third quarter were ¥543 million, down from ¥606 million in the same period of the previous year. - FY2019-Q2Decline in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the second quarter of the current consolidated fiscal year were ¥356 million.」
R&D expenses for the cumulative period through the second quarter were ¥356 million, down from ¥401 million in the same period of the previous year. - FY2019-Q1Decline in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the first quarter of the current consolidated fiscal year were ¥171 million.」
First-quarter R&D expenses were ¥171 million, down from ¥211 million in the same period of the previous year. - FY2018Increase in R&D ExpensesAnnual report
「Total R&D expenses for the current consolidated fiscal year were ¥810 million.」
Full-year R&D expenses were ¥810 million, up from ¥731 million in the previous fiscal year. - FY2018-Q3Increase in R&D ExpensesAnnual report
「The total R&D expenses for the Group during the cumulative period through the third quarter of the current consolidated fiscal year were ¥606 million.」
R&D expenses for the cumulative period through the third quarter were ¥606 million, up from ¥541 million in the same period of the previous year. - FY2018-Q2R&D expenses increased year on yearAnnual report
「The total R&D expenses for the Group during the cumulative period through the second quarter of the current consolidated fiscal year were ¥401 million.」
R&D expenses for the cumulative period through the second quarter were ¥401 million, up from ¥359 million in the same period of the previous year. - FY2018-Q1R&D expenses increased year on yearAnnual report
「The total R&D expenses for the Group during the cumulative period through the first quarter of the current consolidated fiscal year were ¥211 million.」
First-quarter R&D expenses were ¥211 million, up from ¥177 million in the same period of the previous year. - FY2017R&D expenditure declinedAnnual report
「Total R&D expenses for the current consolidated fiscal year were ¥731 million.」
Full-year R&D expenses were ¥731 million, down from ¥833 million in the previous fiscal year. - FY2017-Q3RestatedAnnual report
「The total R&D expenses for the Group during the cumulative period through the third quarter of the current consolidated fiscal year were ¥541 million.」
R&D expenses of ¥541 million were disclosed for the cumulative period through the third quarter. - FY2017-Q2RestatedAnnual report
「The total R&D expenses for the Group during the cumulative period through the second quarter of the current consolidated fiscal year were ¥359 million.」
R&D expenses of ¥359 million were disclosed for the cumulative period through the second quarter. - FY2017-Q1RestatedAnnual report
「The total R&D expenses for the Group during the cumulative period through the first quarter of the current consolidated fiscal year were ¥177 million.」
First-quarter R&D expenses of ¥177 million were disclosed. - FY2016RestatedAnnual report
「Total R&D expenses for the current consolidated fiscal year were ¥833 million.」
Full-year R&D expenses of ¥833 million and the details of R&D activities in the Pharmaceuticals and FC and Chemicals fields were disclosed. - FY2016-Q3RestatedAnnual report
「The total R&D expenses for the Group during the cumulative period through the third quarter of the current consolidated fiscal year were ¥641 million.」
Total R&D expenses of ¥641 million were disclosed for the cumulative period through the third quarter. - FY2016-Q2First statedAnnual report
「The total R&D expenses for the Group during the cumulative period through the second quarter of the current consolidated fiscal year were ¥418 million.」
The total R&D expenses were disclosed.